PCSK2

Across TCGA pan-cancer cohorts, PCSK2 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated PCSK2 data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PCSK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCSK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, BLCA, and UCEC are the cancer types where PCSK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
BLCA	DFS	Median	III,IV	0.113	0.549	.001	18	view →
UCEC	DFS	Median	III,IV	0.915	0.527	.025	16	view →
KIRP	OS	Median	All	0.216	0.904	<.001	15	view →
KIRC	DFS	Median	IV	0.037	0.632	<.001	12	view →
ACC	OS	Median	All	0.147	0.685	.018	12	view →
LGG	OS	Median	All	0.378	0.801	.002	6	view →
HNSC	OS	Median	All	0.177	0.710	.016	6	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	6	view →
SARC	DFS	Median	All	0.167	0.594	.019	3	view →
LUSC	DFS	Median	All	0.136	0.791	.005	3	view →
LIHC	DFS	Median	II,III,IV	0.111	0.429	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

PCSK2–DLBC (OS)

Open the DLBC breakdown →